NASDAQ:TPST

Tempest Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy TPST

*Your capital is at risk

$1.27

-0.0400 (-3.05%)

At Close: Jun 03, 2026

Tempest Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 73.64. In total, the insiders bought 10.24M and sold 1.58M TPST shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	73.64
● Buy	10.24M shares
● Sell	1.58M shares
96% Buy Activity Weak Negative Correlation
Buy Signal High Confidence Mar 24, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 73.64. Confidence increased due to high data reliability score of 90. Supported by overwhelming buy-side pressure (96% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 31, 2026 Buy	Employee Stock Option (right to buy) A-Award	Maestas Nicholas Chief Financial Officer	C-Suite Officer	140 000 Value: $229.6K
Mar 31, 2026 Buy	Employee Stock Option (right to buy) A-Award	Trojanowski Justin Corporate Controller	Officer	22 000 Value: $36.1K
Mar 24, 2026 Buy	Common Stock P-Purchase	Angel Matthew CEO And President	CEO / President	231 482 Value: $500.0K
Feb 04, 2026 Buy	Employee Stock Option (right to buy) A-Award	Angel Matthew CEO And President	CEO / President	269 621 Value: $641.7K
Feb 03, 2026 Buy	Common Stock	Angel Matthew CEO And President	CEO / President	0 Value: $0
Jan 27, 2026 Buy	Stock Option (right to buy) A-Award	Raab Michael Director	Director	1 230 Value: $4K
Jan 27, 2026 Buy	Stock Option (right to buy) A-Award	Nichol Geoffrey Director	Director	1 230 Value: $4K
Jan 27, 2026 Buy	Stock Option (right to buy) A-Award	Simantov Ronit Director	Director	1 230 Value: $4K
Jan 27, 2026 Buy	Stock Option (right to buy) A-Award	Pellizzari Christine A Director	Director	1 230 Value: $4K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Brady Stephen R President And CEO	CEO / President	550 000 Value: $473.0K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Whiting Samuel Chief Medical Officer	Officer	270 000 Value: $232.2K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Trojanowski Justin Corporate Controller	Officer	30 000 Value: $25.8K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Maestas Nicholas Chief Financial Officer	C-Suite Officer	200 000 Value: $172.0K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Maestas Nicholas Chief Financial Officer	C-Suite Officer	200 000 Value: $172.0K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Trojanowski Justin Corporate Controller	Officer	30 000 Value: $25.8K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Whiting Samuel Chief Medical Officer	Officer	270 000 Value: $232.2K
Jan 02, 2025 Buy	Employee Stock Option (right to buy) A-Award	Brady Stephen R President And CEO	CEO / President	550 000 Value: $473.0K
Aug 12, 2024 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	387 999 Value: $427.0K
Aug 12, 2024 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	387 999 Value: $427.0K
Aug 08, 2024 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	400 000 Value: $540.0K
Aug 08, 2024 Sell	Common Stock S-Sale	Versant Venture Capital Vi, L.p. 10 Percent Owner	10% Owner	400 000 Value: $540.0K
Jul 03, 2024 Buy	Common Stock P-Purchase	Brady Stephen R President And CEO	CEO / President	35 000 Value: $73.9K
Jul 03, 2024 Buy	Common Stock P-Purchase	Brady Stephen R President And CEO	CEO / President	35 000 Value: $73.9K
Jul 02, 2024 Buy	Common Stock P-Purchase	Whiting Samuel Chief Medical Officer	Officer	4 672 Value: $10K
Jul 02, 2024 Buy	Common Stock P-Purchase	Whiting Samuel Chief Medical Officer	Officer	4 672 Value: $10K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT TEMPEST THERAPEUTICS INC.

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops T...

Read Full Profile Here